Remdesivir Reduces Death Risk for Hospitalized COVID-19 Patients With Kidney and Liver Disease
Early administration of the antiviral drug remdesivir reduces the risk of 28-day in-hospital death by approximately 24% to 25% in adults hospitalized with COVID-19 who have kidney or liver disease, according to a study published in Clinical Infectious Diseases. Researchers from the University of Illinois and Gilead Sciences found the survival benefit applies to patients regardless of whether they required supplemental oxygen upon admission.
Survival Rates in Patients With Renal and Hepatic Comorbidities
The study analyzed medical claims and hospital cost data for U.S. adults hospitalized for COVID-19 between 2021 and 2025. Researchers tracked 22,378 patients with kidney disease and 5,026 patients with liver disease, comparing those who received early remdesivir initiation against control groups who did not. According to the findings, the risk of all-cause in-hospital death within 28 days was 25% lower for the kidney cohort and 24% lower for the liver cohort among remdesivir recipients.
https://x.com/CIDRAP/status/2094896102147248497
The data showed varying levels of effectiveness based on the severity of respiratory distress:
- Liver patients without supplemental oxygen: Risk of death dropped by 49% with early remdesivir use.
- Liver patients with supplemental oxygen: Risk of death was 26% lower.
- Kidney patients with supplemental oxygen: Risk of death was 25% lower.
For kidney patients who did not require supplemental oxygen, the decrease in death risk was not statistically significant, according to the researchers.
Effectiveness Across Pandemic Variants
A separate large-scale study published in Open Forum Infectious Diseases examined the drug’s impact on patients who did not require supplemental oxygen at admission. This study, also led by Gilead Sciences researchers, spanned the pre-Delta, Delta, and Omicron variant eras from December 2020 to April 2022. Remdesivir was tied to a 25% reduction in 14-day death risk and a 17% reduction in 28-day death risk.
The survival benefit remained consistent across different strains of the virus. The 14-day adjusted hazard ratios (aHR) for death were 0.73 for pre-Delta, 0.80 for Delta, and 0.73 for Omicron. For the 28-day risk, the aHRs were 0.83, 0.87, and 0.76, respectively.
Clinical Considerations for High-Risk Patients
Because remdesivir is primarily metabolized through the liver, the researchers in the Clinical Infectious Diseases study stated that hepatic laboratory testing is recommended both before and during treatment. Despite this, the authors concluded that the evidence supports using the drug for patients with both renal and hepatic comorbidities.
https://x.com/GardenCityBead/status/2094972109776634251
The efficacy of the drug is closely tied to timing. Researchers noted that remdesivir is most effective when administered early in the infection while viral replication is most active. This is evidenced by the study’s focus on patients receiving at least one dose within the first two days of hospital admission.
Comparison of Patient Outcomes
| Patient Group | Death Risk Reduction (28-Day) | Specific Condition/Detail |
|---|---|---|
| Kidney Disease Cohort | 25% Lower | Includes patients requiring renal replacement therapy |
| Liver Disease Cohort | 24% Lower | Includes cirrhosis, liver failure, and noninfectious hepatitis |
| Liver Patients (No Oxygen) | 49% Lower | Risk reduction in liver patients who didn’t receive oxygen |
| General (No Oxygen) | 17% Lower | Across pre-Delta, Delta, and Omicron variants |
Keep reading